The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including World <a target=_blank ...

The drawbacks of retinoids involve the potential for irritancy, which can be concentration- and vehicle-dependent.

Critics believe Donald Trump's nominee to lead Health and Human Services poses a threat to the achievements of a ...

Should Kennedy win Senate confirmation, critics say a radical antiestablishment medical movement would take power.

Federal health scientists brace for RFK Jr.'s potential takeover, with some readying résumés or retirement plans.

Shares of major U.S. drugmakers fell on Friday after President-elect Donald Trump picked anti-vaccine activist Robert F.

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Dupixent has been approved for CSU in Japan and the United Arab Emirates (UAE) and is also under regulatory review in the European Union based on earlier trial readouts. Outside of Japan and the UAE, ...